Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism – The SWAN Study | PLOS ONE
![Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics | Journal of Medicinal Chemistry Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.0c01035/asset/images/large/jm0c01035_0003.jpeg)
Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics | Journal of Medicinal Chemistry
![357189-97-0 | (5R-cis)-4-[5-(2,4-Difluorophenyl)-5-[1,2,4]triazol-1-ylmethyltetrahydrofuran-3-ylmethyl]methoxy-formanilide | 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-(formylamino)phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo ... 357189-97-0 | (5R-cis)-4-[5-(2,4-Difluorophenyl)-5-[1,2,4]triazol-1-ylmethyltetrahydrofuran-3-ylmethyl]methoxy-formanilide | 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-(formylamino)phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo ...](https://www.trc-canada.com/prod-img/D447175.png)